









Markets
/
Stocks
/
nasdaq-imnm
/

Immunome Inc

IMNM

13.920USD

-0.370-2.59%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

1.21BMarket Cap

LossP/E TTM



Immunome Inc

13.920

-0.370-2.59%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Immunome Inc

Currency: USD Updated: 2025-10-09

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immunome Inc's Score

Industry at a Glance

Industry Ranking

33 / 502

Overall Ranking

97 / 4699

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.200

Target Price

+72.73%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Immunome Inc Highlights

StrengthsRisks

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 680.86.

Undervalued

The company’s latest PE is -4.69, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 82.71M shares, decreasing 1.37% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 4.69M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-09

The company's current financial score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 4.01M, representing a year-over-year increase of 69.84%, while its net profit experienced a year-over-year increase of 20.14%.

Score

Industry at a Glance

Previous score

7.26

Change



Financials

9.52

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.61

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.32

Key Metrics

Free cash flow

No Data

Immunome Inc's Company Valuation

Currency: USD Updated: 2025-10-09

The company’s current valuation score is 5.79, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -4.69, which is -70.34% below the recent high of -1.39 and -0.84% above the recent low of -4.73.

Score

Industry at a Glance

Previous score

5.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/502

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-09

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Immunome Inc is 23.50, with a high of 38.00 and a low of 18.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 12 analysts

Buy

Current Rating

24.200

Target Price

+69.35%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Immunome Inc

IMNM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-09

The company’s current price momentum score is 9.59, which is higher than the Biotechnology & Medical Research industry's average of 7.18. Sideways: Currently, the stock price is trading between the resistance level at 16.41 and the support level at 10.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.50

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.672

Buy

RSI(14)

65.995

Neutral

STOCH(KDJ)(9,3,3)

81.410

Neutral

ATR(14)

1.097

High Vlolatility

CCI(14)

95.631

Neutral

Williams %R

17.429

Overbought

TRIX(12,20)

1.511

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

14.090

Sell

MA10

12.869

Buy

MA20

11.438

Buy

MA50

10.537

Buy

MA100

9.928

Buy

MA200

9.454

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-09

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 95.02%, representing a quarter-over-quarter decrease of 4.48%. The largest institutional shareholder is Steven Cohen, holding a total of 4.69M shares, representing 5.38% of shares outstanding, with 387.83% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

6.17M

+58.46%

T. Rowe Price Investment Management, Inc.

8.28M

+9.54%

BlackRock Institutional Trust Company, N.A.

5.17M

+1.22%

Redmile Group, LLC

4.87M

-9.12%

Enavate Sciences GP, LLC

4.77M

Point72 Asset Management, L.P.

Star Investors

4.69M

+7.46%

The Vanguard Group, Inc.

Star Investors

4.51M

+5.08%

EcoR1 Capital, LLC

4.08M

Opaleye Management Inc.

3.53M

-0.58%

PRIMECAP Management Company

Star Investors

3.02M

-11.53%

Risk Assessment

Currency: USD Updated: 2025-10-09

The company’s current risk assessment score is 4.47, which is higher than the Biotechnology & Medical Research industry's average of 3.48. The company's beta value is 1.94. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.